|
(Click sector to view stock chart)
Biotechnology
Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)
REPLIGEN CORPORATION (RGEN)
Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous system. It sells Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain pancreatic disorders. The company sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally. It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration. Repligen has a development agreement with the Stanley Medical Research Institute for a Phase 2 clinical trial of uridine in bipolar depression. The company was founded in 1981 and is based in Waltham, Massachusetts.
BIOMARIN PHARMACEUTICAL INC (BMRN)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises three approved products and various investigational product candidates. The company offers Aldurazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; Naglazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI, an inherited, life-threatening lysosomal storage disorder; and Orapred, a drug primarily used to treat asthma exacerbations in children and other inflammatory conditions. BioMarin is also developing additional proprietary formulations of Orapred, including Orapred ODT (orally disintegrating tablets), which is under U.S. FDA review. In addition, the company is developing various other product candidates, including Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); Phenylase, a preclinical-stage enzyme substitution therapy for the treatment of the more severe form of PKU; and 6R-BH4 for vascular dysfunction. BioMarin has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. and Serono for Phenoptin, Phenylase and 6R-BH4 for cardiovascular indications. The company was founded in 1996 and is headquartered in Novato, California.
ONYX PHARMACEUTICALS INC (ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer. Its primary product includes sorafenib, a Phase III orally available signal transduction inhibitor, inhibits proliferation of cancer cells and angiogenesis. In addition, sorafenib inhibits VEGFR-2 and PDGFR-ß, two proteins involved in angiogenesis, and other proteins that might be implicated in cancer. The company also develops PD 332991, a Phase I clinical trial product, a small molecule cell cycle inhibitor targeting a cyclin-dependent kinase. Onyx Pharmaceuticals has collaboration agreement with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity, of the RAS signaling pathway to treat cancer and other diseases. The company was established in 1992 and is headquartered in Emeryville, California.
XenoPort, Inc. develops and markets applications to enhance bioavailability of drugs. The company's product Transported Prodrug uses transporter genomics, assay technology, and proprietary chemistries to introduce therapeutic molecules into cells. Additionally, it provides solution to improve expiring drugs. XenoPort was founded in 1999 and is headquartered in Santa Clara, California.
Illumina, Inc. engages in the development and marketing of tools for the large-scale analysis of genetic variation and function. Its tools provide information used to improve drugs and therapies, customize diagnoses and treatment, and cure diseases. Its genotyping service product line combines the company's BeadArray technology with an automated, laboratory information management system controlled process to provide throughput identification of the common form of genetic variation, known as single nucleotide polymorphisms. The BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously. This technology includes the BeadArray Reader, GoldenGate assay protocols, laboratory information management system and analytical software, fluid-handling robotics, and access to Sentrix arrays and reagent kits for analyzing genetic sequences. Illumina offers Oligator technology for the parallel synthesis of various oligonucleotides for genomics applications. The company also provides DASL, a gene expression assay, for generating gene expression profiles from RNA samples, including those containing partially degraded RNAs. It offers SNP Genotyping, gene expression profiling, scanning instrumentation, and high-throughput synthesis. Illumina has a strategic collaboration with Invitrogen Corporation to synthesize and distribute oligos. The company markets and distributes its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as to academic or private research centers in North America, Europe, Japan, Singapore, and the Pacific Rim countries. Illumina was founded by John R. Stuelpnagel and Mark Chee in 1998. The company is based in San Diego, California.
INCYTE CORPORATION (INCY)
Incyte Corporation engages in the discovery and development of small molecule drugs to treat medical conditions, including the infection with human immunodeficiency virus (HIV), inflammatory disorders, cancer, and diabetes. Its primary product candidate Reverset is a nucleoside analog reverse transcriptase inhibitor for use in combination with other antiviral drugs for patients with HIV infections, and is in phase IIb clinical trials. In addition, the company's drug discovery programs underway include CCR2 Receptor Antagonist Program and Sheddase Inhibitor Program. CCR2 Receptor Antagonist Program is focused on developing antagonists to a key chemokine receptor involved in inflammation called CCR2. CCR2 is a chemokine receptor found on monocytes that controls their migration into sites of inflammation. The primary products candidate form this program is in phase IIa clinical trial in patients with rheumatoid arthritis. The Sheddase Inhibitor Program involves sheddase inhibitors that would have application in the treatment of breast cancer and other tumor types and is in phase I clinical trials. The company markets its products in the United States and in Austria, Belgium, Canada, France, Denmark, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. Incyte has collaborative agreement with Pharmasset, Inc.; Senomyx, Inc.; Genomic Health, Inc.; Pfizer, Inc.; and Medarex, Inc. Incyte was founded in 1991 and is headquartered in Wilmington, Delaware.
SEQUENOM, Inc., a genetics company, provides genetic analysis products that translate genomic science into superior solutions for biomedical research and molecular medicine. It primarily offers MassARRAY system that includes hardware, software, and consumable products. The MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein. The system delivers data from biological samples and genetic target material that is available in trace amounts. The company offers its products primarily to pharmaceutical and biotechnology companies, laboratories, and governmental and other research institutions in North America, Europe, and Asia. It has strategic collaboration agreements with Bioscientia, Siemens Medical Solutions, and Procter & Gamble Pharmaceuticals. SEQUENOM was established in 1994 and is headquartered in San Diego, California.
COUGAR BIOTECHNOLOGY INC (CGRB)
Cougar Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition and development of therapeutics for the treatment of cancer. It owns the rights to three clinical stage drug candidates, including CB-7630, a targeted inhibitor of the steroidal enzyme for the treatment of advanced prostate cancer patients; CB-3304, an inhibitor of microtubules and tubulin for the treatment of hematological malignancies; and CB-1089, an analog of vitamin D for various tumors, including prostate, breast, pancreas, colon, skin, and brain cancer. The company is also conducting preclinical development of CB-6604, an extended version of CB-3304 for in-vitro studies in breast cancer cells. Cougar Biotechnology was incorporated in 2003 and is based in Los Angles, California.
CHEMGENEX PHARMACEUTICALS LTD (CXSP)
No description available.
SANGAMO BIOSCIENCES INC (SGMO)
Sangamo Biosciences, Inc. engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The company's gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company's technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture. It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy. The company has strategic partnership with Edwards Lifesciences Corporation. Sangamo BioSciences has a research collaboration agreement with Pfizer, Inc. to develop cell lines for enhanced protein production. Sangamo Biosciences was founded in 1995 by Edward Lanphier. The company is headquartered in Richmond, California.
INVITROGEN CORPORATION (IVGN)
Invitrogen Corporation provides products and services that support academic and government research institutions, and pharmaceutical and biotech companies in the United States and Europe. It operates in two segments, BioDiscovery and BioProduction. BioDiscovery segment includes functional genomics, cell biology, and drug discovery product lines. This segment also comprises a range of enzymes, nucleic acids, and other biochemicals and reagents. The company also offers software through this segment that enables analysis and interpretation of genomic, proteomic, and other biomolecular data for application in pharmaceutical, therapeutic, and diagnostic development. BioProduction segment includes various cell culture products and biological testing services. Its products comprise sera, cell, and tissue culture media; reagents used in both life sciences research and in processes to grow cells in the laboratory and to produce pharmaceuticals; and other materials made through cultured cells. BioProduction's services include testing to ensure that biologics are free of disease-causing agents or do not cause adverse effects; characterization of products' chemical structures; development of formulations; and validation of purification processes under regulatory guidelines. It also manufactures biologics on behalf of clients both for use in clinical trials and for the worldwide commercial market. The company serves the life sciences research market; biotechnology, pharmaceutical, energy, agricultural, and chemical companies; and industries that apply genetic engineering to the commercial production. It supplies its products through its own sales force and agents or distributors. Invitrogen has collaboration with Families of Spinal Muscular Atrophy to identify biological targets that are linked to the causes and symptoms of spinal muscular atrophy. The company was founded in 1987 and is headquartered in Carlsbad, California.
CHARLES RIVER LABORATORIES INTERNATIONAL INC (CRL)
Charles River Laboratories International, Inc. provides research tools and integrated support services that enable the drug discovery and development process. It operates in three segments: Research Models and Services (RMS), Preclinical Services, and Clinical Services. RMS segment produces and sells research models, primarily genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist its customers in screening drug candidates. In addition, RMS offers transgenic services, laboratory services, consulting and staffing services, vaccine support, and in vitro technology services. Preclinical Services segment offers services in the areas, such as general and specialty toxicology, pathology, interventional and surgical, biopharmaceutical, pharmacokinetic and metabolic analysis, and bioanalytical chemistry. Clinical Services segment conducts Phase I clinical trials; and provides Phase II-IV clinical trials management services, which include testing, medical data sciences services, and regulatory support. Charles River Laboratories sells its products and services primarily through its direct sales force supplemented by a network of international distributors in the United States, Europe, and Japan. The company's customer base includes pharmaceutical, biotechnology, and animal health and medical device companies, as well as various government agencies, hospitals, and academic institutions. It operates approximately 100 facilities in 20 countries worldwide. Charles River Laboratories was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CHELSEA THERAPEUTICS INTERNATIONAL LTD (CHTP)
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses to acquire and develop products for the treatment of various human diseases. The company develops prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. It also develops therapeutic agent for the treatment of neurogenic orthostatic hypotension and related conditions, and diseases. In addition, the company develops platform technologies that consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, and I-3D portfolio, a dihydroorotate dehydrogenase inhibiting compound. Chelsea Therapeutics' product in development includes CH-1504, an orally available molecule for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis, and cancer. The company was incorporated in 2002 and is based in Charlotte, North Carolina.
SAVIENT PHARMACEUTICALS INC (SVNT)
Savient Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products that target unmet medical needs. It sells and distributes a generic version of oxandrolone, which is used to promote weight gain following involuntary weight loss related to disease or medical condition. The company also sells and distributes the branded version of oxandrolone in the United States, under the name Oxandrin. Further, Savient Pharmaceuticals is developing Puricase, which is in Phase III clinical studies for the control of elevated levels of uric acid in the blood or hyperuricemia. It distributes its products to drug wholesaler customers in the United States. The company was founded in 1980 as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in 2003. Savient Pharmaceuticals is headquartered in East Brunswick, New Jersey.
OBAGI MEDICAL PRODUCTS INC (OMPI)
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally. The company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyper-pigmentation, and acne, as well as soft tissue deficits, such as fine lines and wrinkles. It offers Obagi Nu-Derm System, a prescription-based, topical skin health system on the market that has been shown to enhance the skin's overall health by correcting photo-damage at the cellular level; Obagi-C Rx System, a combination of prescription and OTC drugs and adjunctive cosmetic skin care products to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Obagi Professional-C products, a line of proprietary, non-prescription products, which consist of Vitamin C serums used to reduce the appearance of damage to the skin caused by ultraviolet radiation and other environmental influences. The company also offers Nu-Derm Condition and Enhance System for use in conjunction with commonly performed cosmetic procedures including Botox injections, and ELASTIderm product line, an eye cream for improving the elasticity and skin tone around the eyes; and markets tretinoin, used for the topical treatment of acne in the United States, and Obagi Blue Peel products, used to aid the physician in the application of skin peeling actives. It sells its products through its own domestic sales force and foreign distribution partners to plastic surgeons, dermatologists, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Long Beach, California.
MARTEK BIOSCIENCES CORPORATION (MATK)
Martek Biosciences Corporation engages in the development, manufacture, and sale of products derived from microalgae and other microbes primarily in the United States. Its products include nutritional oils used in infant formula, nutritional supplements, and food fortification ingredients, and fluorescent markers for diagnostics and rapid miniaturized screening. The company's nutritional oils consist of fatty acid components, such as docosahexaenoic acid (DHA) and arachidonic acid (ARA). DHA and ARA help in developing the eyes and central nervous systems of newborns, and DHA helps in promoting adult mental and cardiovascular health. It develops fluorescent detection products from microalgae that connect fluorescent algal proteins to antibodies. These products and technologies enable researchers in drug discovery and diagnostics. Fluorescent detection products include Phycobiliproteins, which are classical direct fluorescent detection dyes and SensiLight dyes that are used to match the sensitivity of chemiluminescent methods. Martek Biosciences markets and sells its nutritional oils primarily to the infant formula and natural products industries. The company has a collaborative agreement with SemBioSys Genetics, Inc., a Canadian biotechnology company, to co-develop plant-based DHA products. Martek Biosciences was founded by Radmer in 1985. The company is based in Columbia, Maryland.
Clinical Data, Inc. offers clinical chemistry and hematology laboratory instrumentation, diagnostic assays, and consulting services for the physician office laboratory (POL), clinics, and smaller hospitals worldwide. The company principally operates through three subsidiaries located in the United States, Netherlands, and Australia. The company's United States subsidiary, Clinical Data Sales & Service, Inc., supplies various products and services, including equipment and reagents, lab management, and consulting services, to the POLs and small and medium sized medical laboratories in the United States. The company's Dutch subsidiary, Vital Scientific NV, designs and manufactures scientific instrumentation marketed worldwide through distributors and strategic partnerships. The company's Australian subsidiary, Vital Diagnostics Pty., Ltd., distributes diagnostic instruments and assays in the south Pacific region. The company provides private labeled blood chemistry analyzers, ESR automated analyzers, diagnostic assays, and consumables, as well as technical support. In addition, it also provides a laboratory information software system for the management and control of smaller laboratories. The company's products are primarily sold through a network of distributors, as well as through dealers and also directly to the end customer. Clinical Data has a collaborative research agreement with the University of Pittsburgh Cancer Institute for metabolomics analysis of lung cancer samples. The company, formerly known as Novitron International, Inc., was founded in 1969 and is headquartered in Newton, Massachusetts.
GILEAD SCIENCES INC (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company's products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.
IDERA PHARMACEUTICALS INC (IDRA)
Idera Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, asthma/allergies, and for use as vaccine adjuvants. It designs proprietary product candidates that are designed to modulate immune responses through Toll-like Receptors, the body's first line of immune defense. The company's DNA chemistry enables it to identify product candidates for the internal development programs and creates opportunities for multiple collaborative alliances. Its drug candidates include IMO-2055, an agonist of TLR9, which is in Phase II trial for renal cell carcinoma; and IMO-2125, a lead product candidate for treating infectious diseases. The company is collaborating with Merck & Co., Inc. to research, develop, and commercialize vaccine products containing its TLR7, 8, or 9 agonists in the fields of oncology, infectious diseases, and Alzheimer's disease. It is also collaborating with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. Idera Pharmaceuticals was founded in 1989. The company was formerly known as Hybridon, Inc. and changed its name to Idera Pharmaceuticals, Inc. in 2005. Idera Pharmaceuticals is based in Cambridge, Massachusetts.
IGI LABORATORIES INC (IG)
IGI, Inc. engages in the production and marketing of cosmetics and skin care products primarily in the United Stares. The company, through its licensed Novasome microencapsulation technologies, engages in the contract manufacture of various dermatological, consumer, skin care, and hair care products. It produces Novasome vesicles for various skin care products. Novasome lipid vesicles are used to encapsulate skin protective agents, oils, moisturizers, shampoos, conditioners, skin cleansers, and fragrances for cosmetics and consumer product applications. IGI also sublicenses the technologies to other companies. In addition, it engages in metal finishing business. The company was incorporated in 1977 and is headquartered in Buena, New Jersey.
Tercica, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve endocrine health. Its first product, Increlex or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved for the long-term treatment of severe Primary IGF-1 deficiency, or Primary IGFD. The company is conducting a Phase IIIb clinical study to evaluate the safety and efficacy of Increlex in children with Primary IGFD. Tercica licensed the rights of Genentech, Inc. to develop, manufacture, and commercialize rhIGF-1 products for a range of indications worldwide. The company was founded in 2000 and is based in Brisbane, California.
QIAGEN N.V., through its subsidiaries, provides enabling technologies and products for the separation, purification, and handling of nucleic acids and proteins. It offers a portfolio of consumable products for nucleic acid and protein separation, purification and handling, and nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products, and related services. Its consumable products applications include plasmid deoxyribonucleic (DNA) acid purification; ribonucleic acid (RNA) stabilization and purification; genomic and viral nucleic acid purification; nucleic acid transfection; PCR amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. Its BioRobot systems offer automation of nucleic acid preparation in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks. The company also offers custom services, small interfering RNA synthesis, whole genome amplification services, DNA sequencing, and noncGMP and cGMP DNA production on a contract basis. The company sells its products to academic research markets, and pharmaceutical and biotechnology companies, as well as developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination, and gene therapy. It operates in the United States, Germany, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands. QIAGEN has a strategic alliance with Eppendorf AG to co-develop and co-market complementary and optimized products. The company was co-founded in 1984 by Detlev H. Riesner and Metin Colpan. QIAGEN is headquartered in Venlo, The Netherlands.
CORCEPT THERAPEUTICS INCORPORATED (CORT)
Corcept Therapeutics Incorporated, a development stage biopharmaceutical company, engages in the development of drugs for the treatment of severe psychiatric and neurological diseases. The company develops CORLUX for the treatment of the psychotic features of psychotic major depression, which is in Phase III clinical trials. Corcept Therapeutics Incorporated was co-founded by Alan Schatzberg and Joseph K. Belanoff. The company was incorporated in 1998 and is based in Menlo Park, California.
OSI PHARMACEUTICALS INC (OSIP)
OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of oncology products for cancer patients in the United States. Its flagship product, Tarceva, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor. The company also markets Novantrone for the approved oncology indications; and Gelclair for the relief of pain associated with oral mucositis. Its other drug candidates include OSI-7904L, a liposomal formulation of a potent thymidylate synthase inhibitor, which is in phase II study; OSI-461, an inhibitor of cGMP phosphodiesterases, which is in phase I dose optimization study; and OSI-930, a tyrosine kinase inhibitor, which is in preclinical research stage. In addition, OSI Pharmaceuticals, through its collaborative drug discovery program, develops CP-547,632, which targets vascular endothelial growth factor receptor and is in Phase II and Phase I trials; CP-868,596 that targets tumor derived angiogenesis and is in Phase I trials; and CP-724,714, which is an oral inhibitor of epidermal growth factor receptor 2 and is in Phase I clinical trial. Further, its subsidiary, Prosidion Limited, specializes in diabetes and obesity treatment in the United Kingdom. The company has collaboration agreements with Pfizer, Inc.; Cold Spring Harbor Laboratory; EiRX Therapeutics plc; Genentech, Inc.; PR Pharmaceuticals, Inc.; and Roche. OSI Pharmaceuticals is headquartered in Melville, New York.
ALNYLAM PHARMACEUTICALS INC (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. The company is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases; and Systemic RNAi to treat a range of diseases, including oncology, metabolic, and autoimmune diseases. Its RNAi development programs are focused on an eye disease, known as age-related macular degeneration; and on a lung infection caused by a virus, known as human respiratory syncytial virus. The company also has multiple preclinical programs in Direct RNAi focused on a central nervous system disorder, known as Parkinson's disease; spinal cord injury; and a genetic disease, known as cystic fibrosis. In addition, Alnylam offers nontherapeutic license agreements to life science reagent and service providers. The company has strategic alliances and research collaborations with Merck & Co., Inc.; Medtronic, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; Mayo Foundation for Medical Education and Research; Novartis AG; and Mayo Clinic Jacksonville. Alnylam was founded by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore in 2002. The company is headquartered in Cambridge, Massachusetts.
IMCLONE SYSTEMS INCORPORATED (IMCL)
ImClone Systems Incorporated, a biopharmaceutical company, engages in developing and commercializing biologic medicines in the area of oncology in the United States. Its research and development programs include growth factor blockers and angiogenesis inhibitors. The company's primary product, ERBITUX, is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy. ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and inhibits the binding of epidermal growth factor and other ligands, such as transforming growth factor-alpha. The company also conducts registration studies evaluating ERBITUX for the treatment of colorectal, head and neck, lung, and pancreatic cancers, as well as other indications. In addition, it develops cancer vaccines, as well as investigational inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. ImClone Systems has collaboration agreements with Bristol-Myers Squibb Company for developing and promoting ERBITUX in the United States, Canada, and Japan; and with Merck KGaA for the development and commercialization of the recombinant gp75 antigen product candidate and ERBITUX. The company was founded in 1984 and is headquartered in New York City.
ACORDA THERAPEUTICS INC (ACOR)
Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III clinical trial for the improvement of walking ability in people with multiple sclerosis. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.
GENZYME CORPORATION (GENZ)
Genzyme Corporation operates as a biotechnology company. Its products and services focuses on rare genetic disorders, renal disease, kidney disease, cancer, orthopaedics, organ transplant, and diagnostic and predictive testing. The company operates in five segments: Renal, Therapeutics, Transplant, Biosurgery, and Diagnostics/Genetics. The Renal unit develops, manufactures, and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The Therapeutics unit offers therapeutic products for genetic diseases; and other chronic debilitating diseases, including lysosomal storage disorders and other specialty therapeutics. The Transplant unit provides therapeutic products that address pretransplantation, prevention, and treatment of acute rejection in organ transplantation, as well as other auto-immune disorders. The Biosurgery unit develops, manufactures, and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. The Diagnostics/Genetics unit offers vitro diagnostic products; and testing services for the oncology, and prenatal and reproductive markets. The company offers its products primarily to physicians, hospitals, and treatment centers in various countries, including the United States, the United Kingdom, Ireland, the Netherlands, Belgium, France, Canada, Switzerland, and Germany. Genzyme Corp. has an agreement with RenaMed Biologics, Inc. to jointly develop and commercialize RenaMed's Bio-Replacement Therapy for the treatment of acute renal failure; a collaboration with De Novo Pharmaceuticals, Ltd. to apply De Novo's molecular structure generating technology to focus on a disease target of interest to Genzyme; and a collaboration agreement with Epiontis GmbH to develop quality control tests for Genzyme's cartilage repair product Carticel. The company was founded in 1981 and is based in Cambridge, Massachusetts.
Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses this product development approach to produce various drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. The company is developing its product candidate programs in various signaling pathways, including the Hedgehog and Bone Morphogenetic Protein pathways. Its lead product candidate is a topical therapy for the treatment of basal cell carcinoma and is under development in collaboration with Genentech, Inc. The company has strategic collaborations with Genentech and Wyeth Pharmaceuticals to develop therapeutics, which modulate the signaling of the Hedgehog pathway; an additional collaboration with Genentech to develop therapeutics that modulate an undisclosed signaling pathway that plays an important role in cell proliferation; and a research and development agreement with Procter & Gamble Pharmaceuticals U.K. Limited to evaluate and develop treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Curis is headquartered in Cambridge, Massachusetts.
SINOVAC BIOTECH LTD (SVA)
Sinovac Biotech, Ltd. engages in the research, development, commercialization, and sale of human-use vaccines and related products for infectious diseases. It offers Healive, a vaccine for hepatitis A; Bilive, a combined vaccine for hepatitis A and B; and Anflu, a split flu vaccine. The company is also developing SARS vaccine, which is in phase I clinical trails, as well as has a co development agreement with the China Centre of Disease Control and Prevention for the development of Avian Flu-Pandemic Influenza Vaccine. Sinovac Biotech was founded in 1999 and is headquartered in Beijing, China.
REGENERON PHARMACEUTICALS INC (REGN)
Regeneron Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical products for the treatment of human disorders and conditions. Its clinical and preclinical pipeline includes product candidates for the treatment of cancer, diseases of the eye, rheumatoid arthritis, and other inflammatory conditions like allergies, asthma, and other diseases and disorders. The company primarily focuses on the development of the VEGF Trap in oncology and eye diseases, which are in phase I clinical trails; and the IL (Interleukin)-1 Trap in various indications in, which interleukin-1 plays a role, including rheumatoid arthritis and other inflammatory conditions. VEGF TRAP is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor, and prevent their interaction with cell surface receptors. Interleukin-1 Trap, which is in preclinical stage, is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors used for the treatment of diseases associated with inflammation in blood vessels. IL-1 Trap is in phase 2b study for its use in rheumatoid arthritis in a double blind, placebo-controlled, and multicenter trial. Regeneron's product candidates in preclinical development stage include Interleukin-4/Interleukin-13 Trap, a protein-based product candidate designed to bind both the interleukin-4 and interleukin-13, which is used for the treatment of diseases, such as asthma, allergic disorders, and other inflammatory diseases. The company also provides contract manufacturing services for the production of an intermediate for a pediatric vaccine. Regeneron has collaboration and licensing agreements with sanofi-aventis Group, Novartis Pharma AG, and The Procter & Gamble Company. The company was founded by Leonard S. Schleifer in 1988. Regeneron is headquartered in Tarrytown, New York.
COMBIMATRIX CORPORATION (CBMX)
Acacia Research Corporation - CombiMatrix engages in the development of technologies and products in the areas of drug development, genetic analysis, nanotechnology research, defense, and homeland security markets. Its platform technologies produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations, and proteins. The company's technology application areas include genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology. Its other technologies include molecular synthesis and screening methods for the discovery of potential new drugs. The company's products are designed to aid in the discovery and development of new drugs and diagnostics for human healthcare. It has collaboration with Novavax, Inc. to develop a technique for in-process monitoring of vaccine production. The company is headquartered in Mukilteo, Washington. Acacia Research Corporation - CombiMatrix operates as a division of Acacia Research Corporation.
SEATTLE GENETICS INC (SGEN)
Seattle Genetics, Inc. develops monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. The company's monoclonal antibody-based technologies include genetically engineered monoclonal antibodies, antibody-drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT), which are used to develop monoclonal antibodies that can kill target cells on their own, as well as increase the potency of monoclonal antibodies. Its product candidate, SGN-30, is in phase II clinical trials, which is used for the treatment of Hodgkin's disease and systemic anaplastic large cell lymphoma; and SGN-15 has completed a phase II clinical trial for use in the treatment of nonsmall cell lung cancer. The company's SGN-40 is in phase I clinical trials in patients with multiple myeloma. In addition, it has four product candidates in preclinical development: SGN-35, SGN-70, SGN-75, and SGN-17/19. The company is conducting preclinical development tests of SGN-35 for the treatment of hematologic malignancies, such as Hodgkin's disease and some types of nonHodgkin's lymphoma. SGN-75 is an ADC composed of an anti-CD70 monoclonal antibody. The CD70 antigen is expressed on renal cancer, nasopharyngeal carcinoma, and certain hematologic malignancies. SGN-17/19, an ADEPT product candidate, is being developed for the treatment of metastatic melanoma. The company has collaboration agreements with Genentech, Celera Genomics Group, UCB Celltech, Protein Design Labs, PSMA Development Company LLC, CuraGen, and Bayer for its ADC technology; and with Genencor for its ADEPT technology. Seattle Genetics was co-founded in 1997 by H. Perry Fell and Clay B. Siegall. The company is headquartered in Bothell, Washington.
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies worldwide. It offers AVONEX, RITUXAN, TYSABRI, ZEVALIN, and AMEVIVE products. The company's AVONEX is approved for the treatment of relapsing forms of multiple sclerosis; RITUXAN is used in the treatment of certain B-cell non-Hodgkin's lymphomas (NHL) or B-cell NHLs; TYSABRI is approved to treat relapsing forms of MS to reduce the frequency of clinical relapses; ZEVALIN used in the treatment of cancer; and AMEVIVE treats adult patients with moderate-to-severe chronic plaque psoriasis. Biogen Idec has collaborations with Genentech, Inc.; Vernalis plc; Elan Corporation, plc; Fumapharm AG; ImmunoGen, Inc.; Sunesis Pharmaceuticals, Inc.; Cellectis SA; and Zenyaku Kogyo Co., Ltd. The company was founded in 1985. It was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec, Inc. in 2003. Biogen Idec is headquartered in Cambridge, Massachusetts.
ENZON PHARMACEUTICALS INC (ENZN)
Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of human therapeutics for life threatening diseases. The company markets four human therapeutic products, such as ABELCET, ONCASPAR, ADAGEN, and DEPOCYT. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is approved in the United States, Canada, and Germany; and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive or allergic to native or unmodified forms of L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the ‘Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. The company also develops PEG-INTRON, which is used in combination with REBETOL for the treatment of chronic hepatitis C; and ATG FRESENIUS S, a polyclonal antibody preparation that is used for T-lymphocyte suppression in organ transplant patients in order to prevent organ graft rejection. The company has strategic alliances with Nektar Therapeutics, SkyePharma, PLC, and Inex Pharmaceuticals Corporation. Enzon Pharmaceuticals was incorporated in 1981 and is headquartered in Bridgewater, New Jersey.
TECHNE CORPORATION (TECH)
TECHNE Corporation, through its subsidiaries, engages in the development and manufacture of biotechnology products and hematology calibrators and controls. The company operates in two divisions, Biotechnology and Hematology. The Biotechnology division engages in the development and manufacture of cytokines and enzymes, antibodies, assay kits, clinical diagnostic kits, flow cytometry products, and intracellular cell signaling products. These products are sold to biomedical researchers and clinical research laboratories. The Hematology division develops and manufactures whole blood hematology controls and calibrators, linearity and reportable range controls, whole blood reticulocyte controls, whole blood flow cytometry controls, whole blood glucose/hemoglobin control, erythrocyte sedimentation rate control, and multipurpose platelet reference controls. These products are sold to hospitals and clinical laboratories to check the performance of hematology instruments. In addition, the company distributes biotechnology products in Europe. The company was founded in 1976 and is based in Minneapolis, Minnesota.
XOMA, Ltd., a biopharmaceutical company, engages in the development and manufacture of antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer, and infectious diseases. The company's proprietary and collaborative product development programs include RAPTIVA, a humanized therapeutic monoclonal antibody, for the treatment of adults for moderate to severe plaque psoriasis; CHIR-12.12, an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies; and NEUPREX, a Phase II clinical trial product, IV formulation of rBPI21, a modified recombinant fragment of bactericidal/permeability-increasing protein for multiple anti-infective and antiendotoxin indications. Its development products also comprise MLN2222, a Phase II clinical trial product, a complement inhibitor under development to reduce the incidence of complications in patients undergoing surgical procedures involving the use of cardiopulmonary bypass; Gastrin, a preclinical antigastrin antibody, for Gastric cancers; ING-1, a Phase I clinical trial product, Human Engineered antibody to Ep-CAM for Adenocarcinomas; and XMP.629, a topical formulation of BPI derived antimicrobial peptide fro acne. XOMA, Ltd. also licenses its proprietary technologies relating to bacterial expression of recombinant pharmaceutical products, as well as its Human Engineering technology that allows modification of any nonhuman monoclonal antibody to reduce or eliminate detectable immunogenicity in humans to biotechnology and pharmaceutical companies. It has collaboration and license agreements with Genentech, Inc.; Chiron Corporation; Zephyr Sciences, Inc.; Millennium Pharmaceuticals, Inc.; Aphton Corporation; Merck & Co., Inc.; Lexicon Genetics Incorporated; Cubist Pharmaceuticals, Inc.; and Triton BioSystems, Inc. The company was founded by Patrick J. Scannon. XOMA, Ltd. was incorporated in 1981 and is headquartered in Berkeley, California.
Cerus Corporation develops products for cancer, infectious disease, and blood safety. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. The company is also developing the INTERCEPT Blood System, which is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens, and white blood cells. This system targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. Cerus is also developing a proprietary vaccine platform to stimulate the immune system to target and attack cancer cells and infectious diseases. The company has collaboration agreements with Baxter Healthcare Corporation and BioOne Corporation for the joint development of the INTERCEPT Blood System for platelets and plasma; and with MedImmune, Inc. to co-develop a therapeutic vaccine designed to treat cancers of the breast, prostate, and colon, as well as metastatic melanomas. Cerus was incorporated in 1991 and is based in Concord, California.
Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The company's principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
Pharmacopeia Drug Discovery, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule therapeutics primarily to address significant medical needs. Using proprietary technologies and processes, Pharmacopeia discovers and develops novel drug candidates to advance internally, as well as with strategic partners. Pharmacopeia's product pipeline includes four compounds in human clinical trials (all Phase I) with various partners, including a compound targeting rheumatoid arthritis in collaboration with Bristol Myers Squibb, a compound targeting asthma and allergies in collaboration with Daiichi Pharmaceutical Corporation, a compound targeting respiratory diseases in collaboration with Schering-Plough, and a compound targeting inflammation in collaboration with Schering-Plough. The company also has 6 additional partnered compounds in preclinical development; 4 internal (nonpartnered) drug candidates; and approximately 20 partnered and internal discovery-stage programs. Pharmacopeia was founded in 1993 and is headquartered in Cranbury, New Jersey.
PONIARD PHARMACEUTICALS INC (PARD)
Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy products in the United States. Its lead product is Picoplatin, a platinum-based cancer therapy, designed to overcome platinum resistance in the treatment of solid tumors. Picoplatin is in Phase II clinical trails in small cell lung cancer and is in Phase I/II trials for colorectal and hormone-refractory prostate cancers. The company has a collaboration agreement with The Scripps Research Institute on the discovery of novel, small-molecule, and multi-targeted protein kinase inhibitors and focal adhesion kinase inhibitors as therapeutic agents, including for the treatment of cancer. Poniard Pharmaceuticals was founded in 1984. It was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in 2006. The company is headquartered in South San Francisco, California.
NPS PHARMACEUTICALS INC (NPSP)
NPS Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of small molecules and recombinant proteins. The company's product candidates are used primarily for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders. NPS's products include PREOS, Calcilytic Compounds, Cinacalcet HCl, Teduglutide, mGluR5 Antagonists, Isovaleramide, Delucemine, Metabotropic Glutamate Receptors, and Glycine Reuptake Inhibitors. The PREOS and Calcilytic Compounds are in phase III and I stage respectively, which are used for the treatment of osteoporosis. The Cinacalcet HCl is in phase II stage, which is used for Hyperparathyroidism. The Teduglutide is in phase II stage and is used for short bowel syndrome or crohn's disease. The mGluR5 Antagonists is in the preclinical stage, which is for gastroesophageal reflux disease. The Isovaleramide is in phase II stage and is used for migraine. The Delucemine is in phase I stage that is used for depression. The Metabotropic Glutamate Receptors is in preclinical stage, which is used for psychiatric and neurologic disorders and pain. The Glycine Reuptake Inhibitors is in preclinical stage that is used for schizophrenia and dementia. The company has collaborative research, development, or license agreements with Amgen, Inc.; AstraZeneca AB; Janssen Pharmaceutical N.V; GlaxoSmithKline; Kirin Brewery, Ltd.; and Nycomed Danmark ApS. The company was founded in 1986 and is headquartered in Salt Lake City, Utah.
CADENCE PHARMACEUTICALS INC (CADX)
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the in-licensing, development, and commercialization of product candidates principally for use in the hospital setting in the United States and Europe. It has two Phase III products in development, including IV APAP for the treatment of acute pain and fever; and Omigard for the prevention of intravascular catheter-related infections. Cadence Pharmaceuticals, formerly known as Strata Pharmaceuticals, Inc., was founded in 2004 and is headquartered in San Diego, California.
CYTORI THERAPEUTICS INC (CYTX)
Cytori Therapeutics, Inc. engages in developing and commercializing stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and serious, chronic, and life threatening conditions. The company develops various products that are in clinical testing stages, which include Celution System, a device that removes stem and regenerative cells from a patient's adipose tissue, as well as used in breast reconstruction applications; Celution PRS System that could be used in plastic and reconstructive surgeries; and Celution CV System for the treatment of chronic myocardial ischemia and heart attacks. Cytori Therapeutics also develops a Celution System, which is under preclinical stage, for investigative applications in gastrointestinal disorders, which could address fistulas and wounds associated with inflammatory disorders, such as Crohn's disease and intestinal repair; peripheral vascular disease; and orthopedic applications, such as bone and spinal disc repair. In addition, it operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Further, Cytori Therapeutics manufactures macropore biosurgery products that include HYDROSORB family of spine and orthopedic implant products; and thin film bioresorbable soft tissue separation implant products. It has strategic joint venture with Olympus Corporation to develop and manufacture future generation devices based on its Celution system. The company was founded in 1996. It was formerly known as MacroPore, Inc. and changed its name to MacroPore Biosurgery, Inc. Further, the company changed its name to Cytori Therapeutics, Inc. in 2005. Cytori Therapeutics is headquartered in San Diego, California.
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has four drug programs in clinical development and in preclinical and discovery stages. Its three clinical programs are ACP-103 for treatment-induced dysfunctions in Parkinson's disease, which is in phase II clinical trails; and ACP-103 and ACP-104, for the treatment of schizophrenia. In addition, the company has neuropathic pain program in Phase I clinical trials and a glaucoma program in preclinical development in collaboration with Allergan, Inc. ACADIA Pharmaceuticals was founded by Mark R. Brann. The company was incorporated as Receptor Technologies, Inc. in 1993 and is headquartered in San Diego, California.
DENDREON CORPORATION (DNDN)
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge (sipuleucel-T), is an investigational active cellular immunotherapy in Phase III clinical trials for the treatment of metastatic, androgen independent prostate cancer. In addition, Dendreon completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and other solid tumors. Its preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease product candidates for the treatment of cancer. The company has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.
CELGENE CORPORATION (CELG)
Celgene Corporation engages in the discovery, development, and commercialization of therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic, and proteomic targets. Its lead product, THALOMID, is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The company, through a supply and distribution agreement, with GlaxoSmithKline, distributes ALKERAN, a therapy for the palliative treatment of multiple myeloma and for palliation of carcinoma of the ovary. Its RITALIN family of drugs includes Focalin (d-MPH), which is used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder in school-age children. The company has various products in the preclinical and clinical-stage, including immunomodulatory drugs and selective cytokine inhibitory drugs. Celgene also produces compounds such as Benzopyrans and Selective Estrogen Receptor Modulators, Kinases Inhibitors, Tubulin Inhibitors, and Ligase Modulators. The company has collaborative agreements with Novartis Pharma AG; and strategic partnership agreements with Pharmion Corporation, Penn Pharmaceuticals Services Limited, and GlaxoSmithKline. The company markets and sells its products in the United States and Canada primarily through wholesale distributors. Celgene was organized in 1980 as a unit of Celanese Corporation and was spun-off in 1986. The company is headquartered in Warren, New Jersey.
TONGJITANG CHINESE MEDICINES COMPANY (TCM)
Tongjitang Chinese Medicines Company focuses on the development, manufacture, marketing, and sale of modernized traditional Chinese medicines. Its primary product, Xianling Gubao, is the traditional Chinese medicine for the treatment of osteoporosis. The company also manufactures and markets a portfolio of 10 other traditional Chinese medicines, including Zaoren Anshen Capsules, an OTC medicine for treating insomnia; and moisturizing and anti-itching capsules, an over-the-counter medicine for treating inflammatory skin conditions. Its product development pipeline includes potential uses of its existing products for additional medical indications and a number of new product candidates that are intended to address the medical needs in the therapeutic areas of women's health, mental health, and dermatology. The company sells its Xianling Gubao and other products exclusively through third-party distributors, who resell the products to hospitals and retail pharmacies in China. Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, China.
Heska Corporation engages in the discovery, development, manufacture, marketing, sale, and distribution of veterinary products. The company operates in two segments, Core Companion Animal Health (CCA); and Other Vaccines, Pharmaceuticals, and Products (OVP). The CCA segment offers diagnostic and monitoring instruments and supplies; single use diagnostic and other tests; vaccines; and pharmaceuticals, primarily for canine and feline use. This segment primarily provides various products, including handheld electrolyte instrument, chemistry instrument, and hematology instrument and their consumables. The OVP segment offers private label vaccine and pharmaceuticals, primarily for cattle, as well as for other animals, including small mammals, horses, and fish. The company sells its products directly, as well as through independent third party distributors and other distribution relationships. The company was incorporated as Paravax, Inc. in 1988 and changed its name to Heska Corporation in 1995. Heska is headquartered in Loveland, Colorado.
INDEVUS PHARMACEUTICALS INC (IDEV)
Indevus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the acquisition, development, and commercialization of products in the fields of urology, gynecology, and infectious diseases. The company markets its product, SANCTURA for the treatment of overactive bladder and has various compounds in clinical development, including SANCTURA XR under phase III program, a once-a-daily formulation of SANCTURA; NEBIDO, which is under phase III trial is used for the treatment of male hypogonadism; PRO 2000, which is under phase I/II clinical trial is used for the prevention of infection by HIV and other sexually transmitted pathogens; IP 751, which is under phase II trial is used for interstitial cystitis; Pagoclone, which is under phase II trial is used for stuttering; and Aminocandin, which is under phase I trial is used for systemic fungal infections. It focuses on the clinical development, regulatory review, and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, Massachusetts.
EXACT SCIENCES CORPORATION (EXAS)
EXACT Sciences Corporation utilizes applied genomics to develop screening technologies for use in the detection of cancer. Certain of its technologies are offered in a commercial testing service, PreGen-Plus, developed by Laboratory Corporation of America Holdings. PreGen-Plus is a non-invasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. EXACT Sciences was founded in 1995 and is headquartered in Marlborough, Massachusetts.
AMICUS THERAPEUTICS INC (FOLD)
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey.
Eurand N.V., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Its lead product candidate includes EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency. The company's product pipeline also comprises EUR-1047, an over-the-counter allergy medication; EUR-1002, which is a formulation of cyclobenzaprine for muscle relaxation; and EUR-1000 a formulation of propranolol for the treatment of hypertension and migraines. Its proprietary drug formulation technologies include customized release technologies to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; dosage form technologies to increase patient compliance through convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technology to improve drug absorption, resulting in dose reduction, and improved onset of action; and drug conjugation technology to extend drug half-life and to target specific organs or other biological targets, such as tumors. The company, formerly known as Eurand B.V., was incorporated in 1984 and is based in Amsterdam, the Netherlands.
PIPEX PHARMACEUTICALS INC (PP)
Pipex Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, engages in the development of proprietary late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Its lead drug candidate includes COPREXA, an oral and anti-copper therapeutic that has completed Phase III clinical trial in neurologically-presenting Wilson's disease. The company has also completed phase II clinical trials for COPREXA, which would be used for the treatment of refractory idiopathic pulmonary fibrosis, a progressive fibrotic lung disease. In addition, it is conducting Phase II clinical trial for COPREXA, which would be used for the treatment of primary biliary cirrhosis. The company completed Phase II clinical trial for TRIMESTA, an oral estriol that is used for the treatment of relapsing-remitting multiple sclerosis, a life threatening autoimmune disease. It also conducts a phase I/II clinical trial for Anti-CD4 802-2 used for the prevention of severe graft versus host diseases, as well as conducts preclinical studies for the treatment of autoimmune diseases. In addition, the company conducts Phase II clinical trial of CORRECTA, a clotrimazole enema for the treatment of refractory acute pouchitis. Further, it plans to conduct Phase II clinical trial for EFFIRMA, which is an oral flupirtine for the treatment of fibromyalgia. Pipex Pharmaceuticals was founded in 2001 and is headquartered in Ann Arbor, Michigan.
ALFACELL CORPORATION (ACEL)
Alfacell Corporation, a development stage company, operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of a class of therapeutic drugs based on its ribonuclease technology for the treatment of cancer, infectious diseases, and other life-threatening conditions. The company focuses primarily on the development of ribonucleases, a family of proteins isolated from the leopard frog. Its product ONCONASE, an amphibian ribonuclease, is in Phase III trial. ONCONASE affects primarily exponentially growing malignant cells. Alfacell also discovered amphinases, a series of proteins, which are bioactive and effective on living cells and organisms, and have both anti-cancer and anti-viral activity. The company was founded by Kuslima Shogen. Alfacell was incorporated in Delaware in 1981 and is based in Bloomfield, New Jersey.
OMRIX BIOPHARMACEUTICALS INC (OMRI)
Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops and markets biosurgical and immunotherapy products derived from human plasma. The company offers a fibrin sealant, used as an adjunct to hemostasis in liver surgery as Evicel in the United States, and as Quixil, used as an adjunct to hemostasis for general surgical use in Germany, the United Kingdom, France, Italy, Brazil, and Mexico, as well as an adjunct to hemostasis in liver and orthopedic surgeries in various European Union countries and Israel. The company's biosurgical products under development include Evicel for use as an adjunct to hemostasis for general surgeries in the United States and the European Union; Fibrin Patch, which is under Phase I clinical trials for the management and control of bleeding, including severe or brisk bleeding, and for use on active bleeding sites. Its developing product portfolio includes Thrombin, which completed Phase III clinical trials for use as an adjunct to hemostasis for general surgeries, primarily for use in neurosurgery in the U.S.; and Adhexil, an investigational new drug for prevention and reduction of post-operative adhesions in patients undergoing pelvic surgery. It also markets immunotherapy products, including VIG to treat smallpox vaccine-related complications under government contracts; IVIG primarily for the treatment of patients with immune deficiency; and HBIG for the prevention of reinfection of transplanted livers with HBV in Israel. The company's immunotherapy products under development include HT-VIG for treatment and prevention of side effects of vaccination against smallpox; WNIG/HT-WNIG to treat severe infection with the West Nile virus, which completed enrollment for Phase I/II clinical trial in the U.S.; and Avian Influenza IG for the treatment of avian influenza. Omrix Biopharmaceuticals, formerly known as Omrix Biopharmaceuticals S.A., was founded in 1995 and is headquartered in New York, New York.
Compugen, Ltd. develops platforms, discovery engines, and related technologies that enable the discovery and analysis of genes and gene-based products, as well as mRNAs and proteins. Its platforms comprise LEADS computational biology platform, which analyzes genomic and expressed sequence data to enable discovery of genes, mRNAs, and proteins; and discovery engines that enable its researchers to identify proteins and mRNAs with predetermined properties for therapeutic and diagnostic development. The company initiates the predictive modeling of alternative splicing, antisense, and the RNA editing that provides the basis for understandings of additional biological phenomena. Compugen has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the company; and additional discoveries that are out-licensed for development. It also focuses on novel splice variants of known and validated therapeutic proteins, as well as novel diagnostic markers. These novel proteins constitute an intellectual property portfolio, which includes novel prostate specific antigens, a novel vascular endothelial growth factor, a splice variant of CD40, and other proteins. The company operates primarily in the United States, Israel, Europe, and the Far East. Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development and commercialization of immunoassay diagnostic markers. The company was established in 1993 and is headquartered in Tel Aviv, Israel.
JAZZ PHARMACEUTICALS INC (JAZZ)
Jazz Pharmaceuticals, Inc. focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome. The company's products in the clinical pipeline include JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-8, a formulation incorporating a benzodiazepine, for the treatment of acute repetitive seizure clusters in refractory epilepsy patients. Its pipeline also comprise JZP-7, a formulation incorporating a dopamine agonist for the treatment of restless legs syndrome; and JZP-2, a formulation of a benzodiazepine for the acute treatment of panic attacks associated with panic disorder. The company has a product development and license agreement with Antares Pharma, Inc. Jazz Pharmaceuticals was founded in 2003 and is headquartered in Palo Alto, California.
ANIKA THERAPEUTICS INC (ANIK)
Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products and devices that are designed to repair, protect and heal bone, cartilage, and soft tissue. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions, and lubricates soft tissues. The company's products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. The ophthalmic products include AMVISC and AMVISC Plus product line, CoEase, STAARVISC-II, and ShellGel. Its injectable ophthalmic viscoelastic products are molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. The company operates in the United States and Canada, the United Kingdom, Italy, and other European countries, Turkey, and parts of the Middle East. Anika Therapeutics was founded in 1983 and is headquartered in Woburn, Massachusetts.
ALSERES PHARMACEUTICALS INC (ALSE)
Alseres Pharmaceuticals, Inc., a development stage biotechnology company, engages in the research and development of biopharmaceutical products for the treatment and diagnosis of central nervous system (CNS) disorders in the United States. Its product candidates include CETHRIN, a recombinant-protein-based drug, which has completed phase I/IIa clinical trial to promote nerve repair after acute spinal cord injury; and ALTROPANE, a molecular imaging agent, which is in phase III clinical trials for the diagnosis of Parkinson's disease (PD). ALTROPANE also has completed its second phase II clinical trial as a diagnostic for Attention Deficit Hyperactivity Disorder (ADHD). The company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke; a Dopamine Transporter blocker for the treatment of PD; and a technetium-based molecular imaging agent for PD and ADHD, as well as Oncomodulin, which is being evaluated as a therapeutic for potential ocular indications, including re-growth of axons after optic nerve injury or damage of retinal ganglion cells from intraocular pressure caused by glaucoma. Alseres Pharmaceuticals has research collaborations with Children's Hospital Boston; Harvard Medical School; MDS Nordion, Inc.; Molecular Neuroimaging, Inc.; QSV Biologics, Ltd.; and Organix, Inc. The company was founded in 1972. It was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. The company is headquartered in Hopkinton, Massachusetts.
AMYLIN PHARMACEUTICALS INC (AMLN)
Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. Its primary drug candidates include exenatide and SYMLIN, which have completed phase III clinical trials for the treatment of diabetes. The company is developing exenatide for the treatment of type II diabetes, as well as studying a sustained release formulation of exenatide. Amylin Pharmaceuticals is developing SYMLIN for the treatment of patients with type I diabetes and insulin-using patients with type II diabetes. SYMLIN injection received the United States Food and Drug Administration approval for use in conjunction with insulin to treat diabetes. The company also has two early stage development programs for the treatment of obesity, including a phase II program for AC137 and AC162352 that completed a Phase I study. In addition, it is studying AC2592, which is in a phase II program for the treatment of patients with severe congestive heart failure, as well as AC3056, which is in phase I program for the treatment of atherosclerosis-related cardiovascular disease. Amylin Pharmaceuticals has a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including sustained release formulations of that compound. It also has a collaboration agreement with Alkermes, Inc. for the development, manufacture, and commercialization of an injectable sustained-release formulation of exenatide. The company was co-founded by Howard E. Greene, Jr in 1987. Amylin Pharmaceuticals is headquartered in San Diego, California.
XTL BIOPHARMACEUTICALS LTD (XTLB)
XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products, primarily for the treatment of neuropathic pain and hepatitis C. Its lead product includes Bicifadine, a serotonin and norepinephrine reuptake inhibitor for the treatment of neuropathic pain. The company also has three products in development, including XTL-2125, a non-nucleoside HCV RNA polymerase inhibitor for the treatment of hepatitis C, which completed Phase I clinical trial; XTL-6865, in Phase Ia clinical trial, for the treatment of hepatitis C; and Diversity Oriented Synthesis, a pre-clinical program focused on the development of novel hepatitis C small molecule inhibitors. It has operations in the United States and Israel. XTL Biopharmaceuticals has license agreements with Dov Pharmaceutical, Inc., B&C Biopharm Co., Ltd., DRK-Blutspendedienst Baden-Wurttemberg, Stanford University, Applied Immunogenetics LLC, VivoQuest, and Yeda. The company was founded in 1993 as Xenograft Technologies, Ltd. and changed its name to XTL Biopharmaceuticals, Ltd. in 1995. XTL Biopharmaceuticals is headquartered in Valley Cottage, New York.
Dyax Corp. engages in the discovery, development, and commercialization of antibodies, small proteins, and peptides as therapeutic products, particularly in the areas of inflammation and oncology. As of December 31, 2004, the company had two product candidates in, or entering into, Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema and for the prevention of blood loss, and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis. In collaboration with Genzyme Corporation, Dyax is conducting an open-label, repeat dose Phase II clinical trial of DX-88. It has completed a Phase I/II study of DX-88 in the United States in patients undergoing coronary artery bypass grafting surgery. The company in collaboration with Debiopharm S.A. for DX-890 has completed two Phase IIa clinical trials, one in adults and one in pediatric cystic fibrosis patients. It uses its proprietary, patented technology, known as phage display, to identify a range of compounds consisting of monoclonal antibodies, small proteins, and peptides with the potential for the treatment of various diseases. The company has 12 discovery programs underway: 7 in oncology, which are focused on the discovery and development of therapies that fight cancer; 4 focused on targets that are believed to be mediators of inflammation; and 1 program focused on an infectious disease target. The company has collaboration agreements with AstraZeneca AB; Dendreon Corporation; Baxter Healthcare S.A.; Biogen Idec, Inc.; Inhibitex, Inc.; Debiopharm S.A.; and Syntonix Pharmaceuticals, Inc. Dyax was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Genentech, Inc., a biotechnology company, engages in the discovery, development, manufacture, and commercialization of biotherapeutics for medical needs. It manufactures and commercializes multiple products for a variety of medical conditions, including cancer, heart attack, allergic asthma, psoriasis, stroke, growth hormone deficiency, and cystic fibrosis in the United States. The company's product portfolio comprises Rituxan, an anti-CD20 antibody; Herceptin, an anti-HER2 antibody; Nutropin Depot growth hormone; Nutropin growth hormone; Protropin growth hormone; Nutropin AQ, a liquid formulation growth hormone; TNKase, a thrombolytic agent; Activase, a tissue plasminogen activator; Cathflo Activase; Pulmozyme, an inhalation solution; Xolair, an anti-IgE antibody; Raptiva, an anti-CD11a antibody; and Avastin, a humanized antibody. It also licenses various additional products to other companies. Genentech's products under development cover various medical conditions, including cancer, respiratory disorders, cardiovascular diseases, endocrine disorders, and inflammatory and immune problems. In addition, the company, jointly with Rinat Neuroscience Corp., develops RI 624, a humanized monoclonal antibody that blocks nerve growth factor. Genentech has collaboration agreements with Array Biopharma, Inc. and Curis, Inc. for the discovery of targeted small-molecule drugs for the treatment of cancer; with Accelerate Brain Cancer Cure relating to Avastin in patients with glioblastoma multiforme, a form of brain cancer; with PIramed, Ltd. to develop anti-cancer drugs; and with Lexicon Genetics, Inc. to discover and develop biotherapeutic drugs. The company's products are sold primarily to wholesalers, specialty distributors, or directly to hospital pharmacies. Genentech was founded by Robert A. Swanson and Herbert W. Boyer in 1975. The company is headquartered in South San Francisco, California.
VIROPHARMA INCORPORATED (VPHM)
ViroPharma Incorporated, a pharmaceutical company, engages in the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. It markets and sells Vancocin Pulvules HCl, the oral capsule formulation, in the United States and its territories. Oral Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous and enterocolitis. The company focuses on product development activities on viral diseases, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. Its products under core development program include CMV with an initial focus on CMV infections in recipients of hematopoietic stem cell/bone marrow transplants, and HCV. Noncore development programs target picornaviruses with intranasal pleconaril. The company has strategic relationships with Glaxo SmithKline, Wyeth, Schering-Plough, and Sanofi-Aventis. ViroPharma was incorporated in 1994 and is based in Exton, Pennsylvania.
TRANSITION THERAPEUTICS INC (TTHI)
Transition Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications. Its lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease, and regenerative therapies E1-I.N.T. and GLP1-I.N.T. for the treatment of diabetes. ELND-005/AZD-103 completed multiple Phase I clinical studies and E1-I.N.T. completed a Phase IIa clinical trial. GLP1-I.N.T. is under preparation for Phase II clinical development. The company is also developing MS-I.E.T. for the treatment of multiple sclerosis and HCV-I.E.T. for the treatment of hepatitis C. In addition, Transition Therapeutics has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. The company has a partnership with Elan Pharma International Limited for the development and commercialization of ELND-005/AZD-103 therapeutic agent. Transition Therapeutics was founded in 1987. It was formerly known as Transition Therapeutics and Diagnostics, Inc. and changed its name to Transition Therapeutics, Inc. in 2000. The company is based in Toronto, Canada.
CV THERAPEUTICS INC (CVTX)
CV Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. Its lead clinical development product includes Ranexa, which would be used for the treatment of chronic angina, a debilitating heart condition. The company also develops Regadenoson, a Phase III clinical trial product, an A2A-adenosine receptor agonist for use as a pharmacologic agent in cardiac perfusion imaging studies; Tecadenoson, a Phase III clinical trial product, an A1-adenosine receptor agonist for the reduction of rapid heart rate during atrial arrhythmias; and Adentri, a Phase II clinical trial product, an A1-adenosine receptor antagonist for the treatment of congestive heart failure. It also has various products in the pre-clinical stage development. It has collaboration agreement with Biogen, Inc. and Fujisawa Healthcare, Inc. In addition, the company is co-promoting ACEON tablets, an angiotensin converting enzyme inhibitor, with its collaborative partner, Solvay Pharmaceuticals, Inc. CV Therapeutics was founded in 1990 and is headquartered in Palo Alto, California.
ONCOLYTICS BIOTECH INC (ONCY)
No description available.
Novavax, Inc. engages in the research, development, and commercialization of products for women's health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. The company's other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.
Medivation, Inc., a biopharmaceutical company, engages in the acquisition, research, and development of various medical technologies. It develops small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and Hormone-Refractory Prostate Cancer. The company develops Dimebon for the treatment of Alzheimer's disease, which is in controlled Phase 2 efficacy study; Dimebon for the treatment of Huntington's disease, which is in a Phase 1-2a study; and proprietary small molecule MDV3100 for Hormone-Refractory Prostate Cancer. The company was founded in 2003 and is based in San Francisco, California.
DISCOVERY LABORATORIES INC (DSCO)
Discovery Laboratories, Inc., a biopharmaceutical company, develops Surfactant Replacement Therapies for respiratory diseases. The company offers Surfaxin, a protein B-based agent, for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories provides Surfaxin, which is in Phase 2 clinical trials, for bronchopulmonary dysplasia in premature infants, neonatal respiratory disorders in premature infants, and prophylactic/early treatment of meconium aspiration syndrome in full-term infants. It also offers its products for the treatment of acute respiratory distress syndrome in adults in the intensive care unit, as well as a Phase 1b trial of its lung surfactant delivered as an inhaled aerosol for patients who suffer from asthma. In addition, the company evaluating the development of aerosolized formulations of its SRT to prevent or treat acute lung injury, COPD, rhinitis, sinusitis, sleep apnea, and otitis media. It has a strategic alliance with Quintiles Transnational Corp.; PharmaBio Development, Inc.; Chrysalis Technologies; and Laboratorios del Dr. Esteve S.A. The company is headquartered in Warrington, Pennsylvania.
ARIAD PHARMACEUTICALS INC (ARIA)
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancer by regulating cell signaling with small molecules. Its lead cancer product candidate, AP23573, is an mTOR inhibitor to treat solid tumors and hematologic malignancies. AP23573 is in multiple Phase II and Ib clinical trials as a single agent in patients with hematologic malignancies and solid tumors. Two multicenter Phase Ib studies with AP23573 in combination with other anti-cancer therapies, which are underway in Europe, focus primarily on patients with breast, ovarian, non-small-cell lung, and prostate cancers, as well as certain sarcomas. ARIAD also has an exclusive license to technology and patents related to certain NF-kB treatment methods, as well as the discovery, development, and use of drugs to regulate NF-kB cell-signaling activity, which might be useful in treating certain diseases. In addition, the company has a partnership with Medinol, Ltd., a cardiovascular medical device company, to develop and commercialize stents and other medical devices to deliver AP23573 to prevent reblockage of injured vessels following stent-assisted angioplasty, a common nonsurgical procedure for dilating or opening narrowed arteries. ARIAD was founded in 1991 by Harvey J. Berger and is headquartered in Cambridge, Massachusetts.
Exelixis, Inc. engages in the discovery and development of pharmaceutical products for the treatment of cancer, metabolic disorders, cardiovascular disease, and other serious diseases. Its clinical development pipeline includes various compounds in cancer and renal disease: XL119 (becatecarin), which is in a Phase III clinical trial in patients with inoperable bile duct tumors and which was exclusively licensed to Helsinn Healthcare SA with rights to reacquire commercial rights for North America; XL647, XL999, XL880, and XL820 that are in Phase I clinical trials in cancer; and XL844 and XL184, anticancer compounds for which it filed investigational new drug applications. The company's preclinical pipeline comprises six programs. The preclinical oncology programs consist of development candidates that focus on inhibiting the RAF (XL281), Akt/S6k (XL418), and IGF1R (XL228) kinases that are implicated in various cancers. In preclinical metabolic disease programs, which consist of Liver X Receptor, Farnesoid X Receptor, and Mineralocortiocoid Receptor programs, the company is developing small molecules that modulate nuclear hormone receptors implicated in various metabolic and cardiovascular disorders. Exelixis has alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, and Genentech. The company was founded as Exelixis Pharmaceuticals, Inc. in 1994 and changed its name to Exelixis, Inc. in 2000. Exelixis is headquartered in South San Francisco, California.
ZymoGenetics, Inc. engages in the discovery, development, and commercialization of therapeutic protein-based products for the treatment of human diseases. Its products include Novolin and NovoRapid marketed worldwide for the treatment of diabetes; NovoSeven marketed worldwide for the treatment of hemophilia; Regranex for the treatment of wound healing; GlucaGen for use as an aid for gastrointestinal motility inhibition and for the treatment of severe hypoglycemia in diabetic patients treated with insulin; and Cleactor for the treatment of myocardial infarction or heart attacks. The company's product pipeline comprises rhThrombin, TACI-Ig, and IL-21. rhThrombin is a topical hemostatic agent intended for the control of bleeding during surgical procedures has completed Phase 2 clinical trial. TACI-Ig is a soluble receptor for the treatment of autoimmune diseases and is developed in collaboration with Serono S.A. IL-21 is a protein for the treatment of cancer. ZymoGenetics was co-founded by Earl W. Davie, Benjamin D. Hall, and Michael Smith in 1981. The company is headquartered in Seattle, Washington.
LA JOLLA PHARMACEUTICAL COMPANY (LJPC)
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of pharmaceutical products in the United States. Its principal product in development is Riquent, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. Riquent is in Phase III clinical trial. The company also develops small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California.
CytRx Corporation, a biopharmaceutical company, engages in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference (RNAi). It owns 3 clinical-stage compounds based on its small molecule ‘molecular chaperone' co-induction technology, as well as a targeted library of 500 small molecule drug candidates that would be used to screen for new drug candidates. The company initiated a Phase II clinical trial with its lead small molecule product candidate, Arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS). Arimoclomol received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration. CytRx has also licensed from the University |
